Equity Overview
Price & Market Data
Price: $0.95
Daily Change: -$0.0099 / 1.04%
Range: $0.95 - $0.99
Market Cap: $34,360,936
Volume: 2,205
Performance Metrics
1 Week: 23.50%
1 Month: %
3 Months: -13.27%
6 Months: 17.22%
1 Year: -4.85%
YTD: -18.33%
Details
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.